Any feedback?
Literature summary for 3.1.4.35 extracted from
- The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus (2009), Br. J. Pharmacol., 156, 909-919.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | impaired vascular cGMP signalling contributes to the development of diabetic vascular and cardiac dysfunction, which can be prevented by chronic phosphodiesterase-5 inhibition | Rattus norvegicus |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| vardenafil | selective inhibitor of phosphodiesterase-5 | Rattus norvegicus |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Rattus norvegicus | - |
- |
- |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| 3',5'-cGMP + H2O | - |
Rattus norvegicus | 5'-GMP | - |
? | |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| PDE5 | - |
Rattus norvegicus |
| phosphodiesterase-5 | - |
Rattus norvegicus |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
